GEN: Spotting Brain Injury in the Bloodstream
Oxeia CEO Michael Wyand is interviewed by Lindsay Gray of Genetic Engineering and Biotechnology News (GEN) on the company’s Phase 2 clinical trial of OXE103 for treating concussions.
Previous
Previous
The Brain Health Magazine: It’s Time to Find a Cure for Concussions
Next
Next